Stay updated with breaking news from Ancer Immunotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Advanced Research Projects Agency for Health (ARPA-H) has awarded $45 million to rapidly develop sense-and-respond implant technology that could slash U.S. cancer-related deaths by more than 50%.
A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.
BeiGene welcomes the return of the immunotherapy’s rights as an opportunity to make it the backbone of its solid tumors strategy. But Novartis cedes an opportunity to gain a competitor to established cancer immunotherapies from Merck and Bristol Myers Squibb.
A recent review in the journal Immunity delves into the crucial role of dendritic cells (DCs) in shaping T-cell responses in cancer, highlighting their importance in both priming anti-tumor immunity and in ongoing immune interactions within tumors. The findings underscore the potential of DCs as key targets for next-generation cancer immunotherapies.
Today, the American Association for Cancer Research (AACR) released the 13th edition of its annual Cancer Progress Report, which chronicles how basic, translational, and clinical cancer research and cancer-related population sciences-;primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)-;remain vitally important to improving health and saving lives.